AKESO grants commercialization rights for Yixinning, receiving a licensing fee of 80 million RMB
Akeso (09926.HK) announced that it has signed an exclusive commercialization rights agreement with JUMPCAN (600566.SH), under which JUMPCAN is authorized to have exclusive commercialization rights for Yixinning (Inusimab Injection), which has been independently developed and approved for listing by the company, in China (excluding Hong Kong, Macau, and Taiwan).
In this cooperation, the company will receive a licensing fee of 80 million RMB, as well as milestone payments of up to 10 million RMB
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments